{"id":32065,"date":"2025-04-18T18:36:16","date_gmt":"2025-04-18T10:36:16","guid":{"rendered":"https:\/\/flcube.com\/?p=32065"},"modified":"2025-04-18T18:36:17","modified_gmt":"2025-04-18T10:36:17","slug":"sanofi-licenses-first-in-class-bsabs-from-earendil-labs-for-autoimmune-and-ibd-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=32065","title":{"rendered":"Sanofi Licenses First-in-Class BsAbs from Earendil Labs for Autoimmune and IBD Treatment"},"content":{"rendered":"\n

French pharmaceutical giant Sanofi (EPA: SAN<\/a>, NASDAQ: SNY<\/a>) has entered into a licensing agreement with US-based Earendil Labs to acquire exclusive worldwide rights to two first-in-class bispecific antibodies (BsAbs) targeting autoimmune and inflammatory bowel diseases (IBD). This strategic move underscores Sanofi’s commitment to expanding its portfolio in these therapeutic areas.<\/p>\n\n\n\n

Agreement Details<\/strong>
Under the terms of the agreement, Sanofi will gain rights to HXN-1002 and HXN-1003, which were developed using Earendil’s proprietary AI-driven high-throughput discovery platform. Earendil will receive an upfront payment of USD 125 million, with the potential for total payments reaching up to USD 1.72 billion. These payments are contingent upon the achievement of specific development, regulatory, and commercial milestones. Additionally, Earendil is set to receive a USD 50 million near-term milestone payment, along with tiered royalties ranging from high-single-digit to low-double-digit percentages on net sales.<\/p>\n\n\n\n

Product Potential<\/strong>
HXN-1002 and HXN-1003 represent significant advancements in the treatment of autoimmune and inflammatory diseases. Their development leverages Earendil’s innovative AI platform, which accelerates the discovery and optimization of novel therapeutic candidates. This partnership positions Sanofi to offer new treatment options for patients suffering from conditions such as inflammatory bowel disease, where there remains a substantial unmet medical need.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

French pharmaceutical giant Sanofi (EPA: SAN, NASDAQ: SNY) has entered into a licensing agreement with…<\/p>\n","protected":false},"author":1,"featured_media":32067,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[65,4017,931,28,867,147],"class_list":["post-32065","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-auto-immune","tag-earendil-labs","tag-epa-san","tag-multi-specific-antibodies","tag-nasdaq-sny","tag-sanofi"],"yoast_head":"\nSanofi Licenses First-in-Class BsAbs from Earendil Labs for Autoimmune and IBD Treatment - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"French pharmaceutical giant Sanofi (EPA: SAN, NASDAQ: SNY) has entered into a licensing agreement with US-based Earendil Labs to acquire exclusive worldwide rights to two first-in-class bispecific antibodies (BsAbs) targeting autoimmune and inflammatory bowel diseases (IBD). This strategic move underscores Sanofi's commitment to expanding its portfolio in these therapeutic areas.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=32065\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sanofi Licenses First-in-Class BsAbs from Earendil Labs for Autoimmune and IBD Treatment\" \/>\n<meta property=\"og:description\" content=\"French pharmaceutical giant Sanofi (EPA: SAN, NASDAQ: SNY) has entered into a licensing agreement with US-based Earendil Labs to acquire exclusive worldwide rights to two first-in-class bispecific antibodies (BsAbs) targeting autoimmune and inflammatory bowel diseases (IBD). This strategic move underscores Sanofi's commitment to expanding its portfolio in these therapeutic areas.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=32065\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-18T10:36:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-18T10:36:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1819.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32065#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32065\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sanofi Licenses First-in-Class BsAbs from Earendil Labs for Autoimmune and IBD Treatment\",\"datePublished\":\"2025-04-18T10:36:16+00:00\",\"dateModified\":\"2025-04-18T10:36:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32065\"},\"wordCount\":214,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32065#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1819.webp\",\"keywords\":[\"Auto-immune\",\"Earendil Labs\",\"EPA: SAN\",\"Multi-specific antibodies\",\"NASDAQ: SNY\",\"Sanofi\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32065#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32065\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=32065\",\"name\":\"Sanofi Licenses First-in-Class BsAbs from Earendil Labs for Autoimmune and IBD Treatment - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32065#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32065#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1819.webp\",\"datePublished\":\"2025-04-18T10:36:16+00:00\",\"dateModified\":\"2025-04-18T10:36:17+00:00\",\"description\":\"French pharmaceutical giant Sanofi (EPA: SAN, NASDAQ: SNY) has entered into a licensing agreement with US-based Earendil Labs to acquire exclusive worldwide rights to two first-in-class bispecific antibodies (BsAbs) targeting autoimmune and inflammatory bowel diseases (IBD). This strategic move underscores Sanofi's commitment to expanding its portfolio in these therapeutic areas.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32065#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32065\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32065#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1819.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1819.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sanofi Licenses First-in-Class BsAbs from Earendil Labs for Autoimmune and IBD Treatment\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32065#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sanofi Licenses First-in-Class BsAbs from Earendil Labs for Autoimmune and IBD Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sanofi Licenses First-in-Class BsAbs from Earendil Labs for Autoimmune and IBD Treatment - Insight, China's Pharmaceutical Industry","description":"French pharmaceutical giant Sanofi (EPA: SAN, NASDAQ: SNY) has entered into a licensing agreement with US-based Earendil Labs to acquire exclusive worldwide rights to two first-in-class bispecific antibodies (BsAbs) targeting autoimmune and inflammatory bowel diseases (IBD). This strategic move underscores Sanofi's commitment to expanding its portfolio in these therapeutic areas.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=32065","og_locale":"en_US","og_type":"article","og_title":"Sanofi Licenses First-in-Class BsAbs from Earendil Labs for Autoimmune and IBD Treatment","og_description":"French pharmaceutical giant Sanofi (EPA: SAN, NASDAQ: SNY) has entered into a licensing agreement with US-based Earendil Labs to acquire exclusive worldwide rights to two first-in-class bispecific antibodies (BsAbs) targeting autoimmune and inflammatory bowel diseases (IBD). This strategic move underscores Sanofi's commitment to expanding its portfolio in these therapeutic areas.","og_url":"https:\/\/flcube.com\/?p=32065","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-18T10:36:16+00:00","article_modified_time":"2025-04-18T10:36:17+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1819.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=32065#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=32065"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sanofi Licenses First-in-Class BsAbs from Earendil Labs for Autoimmune and IBD Treatment","datePublished":"2025-04-18T10:36:16+00:00","dateModified":"2025-04-18T10:36:17+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=32065"},"wordCount":214,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=32065#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1819.webp","keywords":["Auto-immune","Earendil Labs","EPA: SAN","Multi-specific antibodies","NASDAQ: SNY","Sanofi"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=32065#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=32065","url":"https:\/\/flcube.com\/?p=32065","name":"Sanofi Licenses First-in-Class BsAbs from Earendil Labs for Autoimmune and IBD Treatment - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=32065#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=32065#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1819.webp","datePublished":"2025-04-18T10:36:16+00:00","dateModified":"2025-04-18T10:36:17+00:00","description":"French pharmaceutical giant Sanofi (EPA: SAN, NASDAQ: SNY) has entered into a licensing agreement with US-based Earendil Labs to acquire exclusive worldwide rights to two first-in-class bispecific antibodies (BsAbs) targeting autoimmune and inflammatory bowel diseases (IBD). This strategic move underscores Sanofi's commitment to expanding its portfolio in these therapeutic areas.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=32065#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=32065"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=32065#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1819.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1819.webp","width":1080,"height":608,"caption":"Sanofi Licenses First-in-Class BsAbs from Earendil Labs for Autoimmune and IBD Treatment"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=32065#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sanofi Licenses First-in-Class BsAbs from Earendil Labs for Autoimmune and IBD Treatment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1819.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32065","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=32065"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32065\/revisions"}],"predecessor-version":[{"id":32068,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32065\/revisions\/32068"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/32067"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=32065"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=32065"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=32065"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}